EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Lupus Nephritis Risk Factors and Biomarkers: An Update

Yves Renaudineau iD, Wesley Brooks iD, Julie Belliere

International Journal of Molecular Sciences · 25.09.2023 · 24 (19) · 14526

DOI: 10.3390/ijms241914526 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.09.2023. Verfasst von Yves Renaudineau und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Referral Medical Biology Laboratory, University Hospital of Toulouse, Institut National de la Santé Et de la Recherche Médi…. Hauptthemen laut MEDLINE: Lupus Nephritis, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lupus nephritis (LN) represents the most severe organ manifestation of systemic lupus erythematosus (SLE) in terms of morbidity and mortality. To reduce these risks, tremendous efforts have been made in the last decade to characterize the different steps of the disease and to develop biomarkers in order to better (i) unravel the pre-SLE stage (e.g., anti-nuclear antibodies and interferon signature); (ii) more timely initiation of therapy by improving early and accurate LN diagnosis (e.g., pathologic classification was revised); (iii) monitor disease activity and therapeutic response (e.g., recommendation to re-biopsy, new urinary biomarkers); (iv) prevent disease flares (e.g., serologic and urinary biomarkers); (v) mitigate the deterioration in the renal function; and (vi) reduce side effects with new therapeutic guidelines and novel therapies. However, progress is poor in terms of improvement with early death attributed to active SLE or infections, while later deaths are related to the chronicity of the disease and the use of toxic therapies. Consequently, an individualized treat-to-target strategy is mandatory, and for that, there is an unmet need to develop a set of accurate biomarkers to be used as the standard of care and adapted to each stage of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisLupus Erythematosus, SystemicHumansBiomarkersAntibodies, AntinuclearRisk Factors

Stichwörter der Autor:innen

autoantibodiesbiomarkerslupus nephritisrenal biopsyurinary markers

Substanzen

BiomarkersAntibodies, Antinuclear

Autor:innen und Institutionen

  • Department of Immunology, Referral Medical Biology Laboratory, University Hospital of Toulouse, Institut National de la Santé Et de la Recherche Médicale (INSERM) U1291, Centre National de la Recherche Scientifique (CNR…
  • Department of Chemistry, University of South Florida, Tampa, FL 33620, USA.
  • Department of Nephrology and Organ Transplantation, Referral Centre for Rare Kidney Diseases, University Hospital of Toulouse, INSERM U1297, 31400 Toulouse, France.

ORCID-Profile: Yves Renaudineau, Wesley Brooks

Zitieren

APA

Renaudineau, Y., Brooks, W., & Belliere, J. (2023). Lupus Nephritis Risk Factors and Biomarkers: An Update. International Journal of Molecular Sciences, 24(19), 14526. https://doi.org/10.3390/ijms241914526

Vancouver

Renaudineau Y, Brooks W, Belliere J. Lupus Nephritis Risk Factors and Biomarkers: An Update. International Journal of Molecular Sciences. 2023;24(19):14526. doi:10.3390/ijms241914526

BibTeX
@article{Renaudineau2023,
  author = {Renaudineau, Yves and Brooks, Wesley and Belliere, Julie},
  title = {Lupus Nephritis Risk Factors and Biomarkers: An Update},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {19},
  pages = {14526},
  doi = {10.3390/ijms241914526}
}
Kostenlos starten →